Q-omics provides the consensus-scored CCR5AS profile across patient tissues and cancer cell-line models. CCR5AS expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CCR5AS is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, CCR5AS RNA expression shows 17,732 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where CCR5AS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCR5AS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCR5AS survival associations across molecular data types. CCR5AS RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCR5AS RNA expression–survival associations across cancer types. High CCR5AS expression shows unfavorable associations in STAD, LGG, KICH and LUSC, but favorable associations in SKCM and CESC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for CCR5AS RNA expression.
This table summarizes CCR5AS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CCR5AS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCR5AS shows lower tumor expression in LUSC and higher tumor expression in KIRC, COAD, STAD, KIRP and THCA. The KIRC box plot shows higher CCR5AS RNA expression in tumor versus normal tissue (log2 FC = +1.416, t-test p < 0.001).
This table shows molecular features associated with CCR5AS in patient tissues and cancer cell lines. In patient samples, CCR5AS shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
